A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide

JPEN J Parenter Enteral Nutr. 2016 Jul;40(5):725-9. doi: 10.1177/0148607114566466. Epub 2015 Jan 7.

Abstract

Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted in approval of the drug by the Food and Drug Administration in 2012 as a treatment for parenteral nutrition-dependent short bowel syndrome in adults. This report presents the case study of a man with short bowel syndrome caused by portal vein thrombosis who had 4 years exposure to the drug at the time of his death due to cardiovascular disease.

Keywords: cardiovascular; glucagon-like peptide 2; growth factors; malabsorption; short bowel syndrome; teduglutide.

Publication types

  • Case Reports

MeSH terms

  • Cardiovascular Diseases / complications*
  • Fatal Outcome
  • Gastrointestinal Agents*
  • Heart Failure
  • Humans
  • Male
  • Middle Aged
  • Parenteral Nutrition*
  • Peptides / adverse effects
  • Peptides / therapeutic use*
  • Portal Vein
  • Randomized Controlled Trials as Topic
  • Short Bowel Syndrome / etiology
  • Short Bowel Syndrome / therapy*
  • Thrombosis / complications

Substances

  • Gastrointestinal Agents
  • Peptides
  • teduglutide